Evidence map›Paper›PMID 32719770›Full record

ArticleFrontiers in chemistry2020

Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An

Mallikarjuna Rao Gedda, Prasoon Madhukar, Alok Kumar Vishwakarma, Vimal Verma, Anurag Kumar Kushwaha, Ganesh Yadagiri, Shyam Lal Mudavath, Om Prakash Singh, Onkar Nath Srivastava, Shyam Sundar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Approved drugs successfully repurposed againstFrontiers in cellular and infection microbiology · 2024
    Article
  7. Review
  8. Review
  9. Review
  10. Nanodiagnostics in leishmaniasis: A new frontiers for early elimination.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mallikarjuna Rao GeddaInfectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Prasoon MadhukarInfectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Alok Kumar VishwakarmaDepartment of Physics, Institute of Science, Banaras Hindu University, Varanasi, India.
Vimal VermaInfectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Anurag Kumar KushwahaInfectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Ganesh YadagiriInfectious Disease Biology Laboratory, Chemical Biology Unit, Institute of Nano Science and Technology, Habitat Centre, Mohali, India.
Shyam Lal MudavathInfectious Disease Biology Laboratory, Chemical Biology Unit, Institute of Nano Science and Technology, Habitat Centre, Mohali, India.
Om Prakash SinghInfectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Onkar Nath SrivastavaDepartment of Physics, Institute of Science, Banaras Hindu University, Varanasi, India.
Shyam SundarInfectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Institute of Medical Sciences · INBanaras Hindu University · INIndia Habitat Centre · IN

Funding

Visceral Leishmaniasis in Bihar State, IndiaP50AI074321 · NIAID · BANARAS HINDU UNIVERSITY · PI SUNDAR, SHYAM · 2007 to 2016
$6.4M
Visceral Leishmaniasis in Bihar State, IndiaU19AI074321 · NIAID · BANARAS HINDU UNIVERSITY · PI SUNDAR, SHYAM · 2017 to 2021
$2.8M
NIAID NIH HHS P50 AI074321NIAID NIH HHS U19 AI074321
6 · The paper itself

Abstract

Visceral leishmaniasis (VL) has been a major health concern in the developing world, primarily affecting impoverished people. It is caused by a protozoan parasite

Indexed as

antileishmanial activitycytotoxicitygraphene-CNT compositenanoparticlesvisceral leishmaniasis

Identifiers

PMID32719770
PMCPMC7350933
OpenAlexW3040297898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.